pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

663 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1167Endpoints883BioPharma Dive340BioSpace303Fierce Biotech283onclive165raps104globenewswire health73
therapy area
allOncology7505Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1192Pulmonology1127Psychiatry & CNS864
  • Industry and rare disease groups call for more transparency in FDA voucher pilot
    The pharmaceutical industry and rare‑disease advocacy groups have voiced concerns about the Commissioner's National Priority Voucher pilot program. Stakeholders say the program lacks transparency…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Texas attorney general probes energy drink safety as federal research ethics office shrinks dramatically
    The Texas attorney general has opened an inquiry into the safety and marketing claims of popular energy drinks, seeking to determine whether they pose health risks or violate state consumer protect…
    STAT · 3mo agoRegulatoryNeutral↗ source
← prev
page 21 of 27
next →
fda recalls67
fda medwatch60
fda press38
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
  • Physician’s personal emergency highlights safety concerns in universal health care systems
    Nisha Narayanan, a clinical assistant professor of pediatrics who splits her practice between New York City and Edinburgh, reflects on how moving abroad reshaped her views on health care. Three we…
    STAT · 3mo agoNeutral↗ source
  • AI pioneer Jakob Uszkoreit’s Inceptive Nucleics teams with Alnylam as biotech lobby pushes Congress for DNA safeguards
    Jakob Uszkoreit, one of the architects behind the transformer model that powers ChatGPT, has turned his attention to drug development. His new venture, Inceptive Nucleics, is creating biological fo…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Grail’s Galleri multi-cancer early detection trial misses primary endpoint, but oncologists note promising signals
    The first randomized trial of a multi-cancer early detection test enrolled about 143,000 English adults aged 50 to 77. Participants were randomly assigned to receive either standard care or the Gal…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Eli Lilly cuts German weight-loss syringe investment by half amid new cost-cutting law
    Eli Lilly said it will cut its planned investment in Germany for the production of weight‑loss syringes. The company had originally earmarked $2.67 billion, but will now invest roughly half that a…
    STAT · 3mo agoDealNegative↗ source
  • Acting FDA chief vows to shield rare-disease discussions from political influence
    Acting FDA Commissioner Kyle Diamantas met with executives from fifteen rare‑disease nonprofit groups and senior agency staff. During the gathering he emphasized a new approach that differs from th…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • HHS says Americans with high-risk Ebola exposure can receive experimental antibody MBP-134 from Mapp Biopharma
    HHS announced that U.S. citizens who have had high-risk exposure to Ebola in the ongoing Central African outbreak will be eligible to receive an experimental antibody therapy. The treatment, ident…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Health secretary RFK Jr. faces staffing gaps as top priority over vaccine initiatives
    Robert F. Kennedy Jr., in his second year as the nation’s health secretary, has spent much of the first half of the year traveling to farms, clinics and other sites across the United States. In in…
    STAT · 3mo agoNeutral↗ source
  • Alnylam inks up to $2 billion AI partnership with Inceptive Nucleics for RNAi drug discovery
    Alnylam announced a three-year strategic collaboration with Inceptive Nucleics to develop AI foundation models for RNAi therapeutics. The agreement is valued at up to $2 billion, with an initial $…
    STAT · 3mo agoDealPositive↗ source
  • Highmark Health sues HaloMD over alleged sham arbitration letter and misleading price data
    Highmark Health, a Pennsylvania Blue Cross Blue Shield licensee with more than 7 million members, filed a complaint on June 1 in U.S. District Court in Western Pennsylvania accusing HaloMD of abusi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Legend Biotech shares jump 40% after promising early CAR-T data in Non-Hodgkin’s lymphoma
    Shares of Legend Biotech rose more than 40% after the company released early results from its in vivo CAR‑T therapy targeting Non‑Hodgkin’s lymphoma. The data showed encouraging activity and a mana…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Trump administration's new Medicaid work-requirement rules surprise states and patients
    Medicaid leaders and advocates say they are shocked by the Trump administration's latest directives that tighten work‑requirement rules for the program, a shift from the tone of earlier federal sta…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Military culture may increase risk of eating disorders among men, expert warns
    Paula Chesley, a yoga and meditation instructor who works with people with eating disorders, notes that male clients are rare but many have served in the military. She says that, based on her expe…
    STAT · 3mo agoNegative↗ source
  • FDA releases draft guidance to speed cell and gene therapy approvals
    The FDA announced a draft guidance aimed at helping developers bring gene therapies to patients more quickly. It encourages use of publicly available scientific data and existing platform knowledge…
    fda press · 3mo agoRegulatoryNeutral↗ source
  • AbiVax shares plunge as safety concerns shadow strong ulcerative colitis trial results
    AbiVax reported Phase 3 data for its experimental therapy obefazimod in patients with moderately to severely active ulcerative colitis. Two dose levels achieved placebo‑adjusted clinical remission…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipeline
    Travere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly warns 340B hospitals to submit claims data within five days or lose price discounts
    Eli Lilly has given roughly 50 hospitals that participate in the federal 340B drug discount program a five‑day deadline to provide comprehensive claims data. The company says that if the data are n…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Trump administration releases Medicaid work-requirement rules, prompting state compliance challenges
    The Morning Rounds newsletter highlighted several health‑policy developments, notably new Medicaid work‑requirement rules and fast‑tracked funding for experimental Ebola vaccines. The Trump admini…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B deal
    Servier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billion
    French pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…
    STAT · 3mo agoDealPositive↗ source
  • CEPI allocates $62 million to accelerate three Bundibugyo Ebola vaccine candidates
    CEPI announced it will provide roughly $62 million to three groups to speed the development of vaccines targeting the Bundibugyo strain of Ebola, which is currently spreading in the Democratic Repu…
    STAT · 3mo agoDealPositive↗ source
  • Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy support
    Orphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…
    BioPharma Dive · 3mo agoPositive↗ source
  • ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy Lin
    At the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…
    STAT · 3mo agoNeutral↗ source
  • General Catalyst uses Summa Health as test bed for AI-driven patient support tools
    General Catalyst bought Ohio safety‑net hospital Summa Health in October and is using it to trial new health‑technology tools. Executives from the holding company, Health Assurance Transformation C…
    STAT · 3mo agoPositive↗ source